Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bharat ParenteralsNSE:BPLPHARMA +1.60%55 Return-on-Tangible-Equity is 1.50% as of Jun. 2026, which is 88% below its 10-year median of 12.40. GuruFocus rates NSE:BPLPHARMA with a GF Score™ of 55/100 and a GF Value™ of ₹1,232.25 (Fairly Valued). The stock has 5 warning signs investors should review. Among 894 Drug Manufacturers companies, Bharat Parenterals ranks worse than 77.18% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bharat Parenterals's annualized net income for the quarter that ended in Jun. 2026 was ₹40 Mil. Bharat Parenterals's average shareholder tangible equity for the quarter that ended in Jun. 2026 was ₹2,686 Mil. Therefore, Bharat Parenterals's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 1.50%.
The historical rank and industry rank for Bharat Parenterals's Return-on-Tangible-Equity or its related term are showing as below:
NSE:BPLPHARMA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -5.94 Med: 12.4 Max: 25.47
Current: -5.94
During the past 13 years, Bharat Parenterals's highest Return-on-Tangible-Equity was 25.47%. The lowest was -5.94%. And the median was 12.40%.
NSE:BPLPHARMA's Return-on-Tangible-Equity is ranked worse than 77.18% of 894
companies
in the Drug Manufacturers industry
Industry Median: 7.895
vs NSE:BPLPHARMA: -5.94
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bharat Parenterals Return-on-Tangible-Equity Related Terms
Bharat Parenterals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bharat Parenterals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BPLPHARMA vs : Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bharat Parenterals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bharat Parenterals Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bharat Parenterals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bharat Parenterals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 1.50% mean?
Bharat Parenterals (NSE:BPLPHARMA) has a Return-on-Tangible-Equity of 1.50% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bharat Parenterals and its competitors. This is 88% below median its historical median of 12.40. According to the industry distribution chart, Bharat Parenterals ranks #690 out of 894 companies in the Drug Manufacturers industry, placing it in the top 77.2%.
Is Bharat Parenterals' Return-on-Tangible-Equity too high?
Bharat Parenterals' current Return-on-Tangible-Equity of 1.50% is 88% below median its 10-year median of 12.40. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Bharat Parenterals' value of 1.50% is 81% below this industry median. Based on the distribution chart, Bharat Parenterals ranks #690 out of 894 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bharat Parenterals has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bharat Parenterals' Return-on-Tangible-Equity compare to ?
According to the Drug Manufacturers industry distribution chart, Bharat Parenterals ranks #690 out of 894 companies for Return-on-Tangible-Equity. This places Bharat Parenterals in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Bharat Parenterals' value of 1.50% is 81% below this benchmark. While the company's 10-year median is 12.40 vs. the industry median of 7.90, Bharat Parenterals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 894 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bharat Parenterals's current Return-on-Tangible-Equity of 1.50% is 81% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bharat Parenterals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bharat Parenterals's current Return-on-Tangible-Equity is 1.50%, which is 88% below median its own 10-year median of 12.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bharat Parenterals stock overvalued right now?
Based on GuruFocus' analysis, Bharat Parenterals (NSE:BPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,232.25, compared to a current price of ₹1,294.70 — trading 5.1% above its estimated fair value. The current Return-on-Tangible-Equity is 1.50%, which is 88% below median its 10-year median of 12.40 and 81% below the Drug Manufacturers industry median of 7.90. Bharat Parenterals' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bharat Parenterals (NSE:BPLPHARMA), the current Return-on-Tangible-Equity is 1.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bharat Parenterals (NSE:BPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Bharat Parenterals stock appears to be overvalued.
The current stock price of ₹1,294.70 is trading 5.1% above its estimated GF Value™ of ₹1,232.25.
GuruFocus considers Bharat Parenterals to be Fairly Valued.
Key valuation signals for NSE:BPLPHARMA:
Return-on-Tangible-Equity: 1.50% (88% below median its 10-year median of 12.40)
GF Value™: ₹1,232.25 vs. price of ₹1,294.70 (5.1% above fair value)
Industry Position: 81% below the Drug Manufacturers median (#690 of 894)
No single metric tells the full story. See the NSE:BPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bharat Parenterals Ltd is a pharmaceutical company. It provides various products such as Capsules, Dry Syrups, Sachets, Oral Liquids, Injections, Semisolids, and others. Geographically, the group has a business presence in India and Outside India.
55GF Score
Get the complete analysis for NSE:BPLPHARMA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BPLPHARMA has been successfully added to your 
